The first indication in which crizotinib demonstrated important clinical activities was in metastatic NSCLC patients with ALK-rearrangement, which led to a regulatory approval of the drug by the FDA in 2011 [18,21,22]. This evidence concerns the gene ALK and non-small cell lung carcinoma.